Immunogenetics

, Volume 65, Issue 2, pp 91–96 | Cite as

A genetic variant of FcγRIIIa is strongly associatedwith humoral immunity to cyclin B1 in African American patients with prostate cancer

  • Janardan P. Pandey
  • Aryan M. Namboodiri
  • Emily Kistner-Griffin
Original Paper

Abstract

There are significant inter-individual differences in naturally occurring antibody responses to the tumor-associated antigen cyclin B1 in healthy subjects with no history of cancer as well as in patients with multiple types of cancer, but the host genetic factors that might contribute to these differences have not been identified. The aim of the present investigation was to determine whether the variation in endogenous antibody levels to cyclin B1 in patients with prostate cancer was associated with immunoglobulin GM and KM alleles, expressed on the constant regions of γ and κ chains, respectively. We also aimed to determine whether particular Fcgamma receptor (FcγR) genotypes, which have been implicated in the immunobiology of several cancers, contribute to the magnitude of humoral immunity to cyclin B1. DNA samples from 129 Caucasian American (CA) and 76 African American (AA) patients with prostate cancer were genotyped for several GM, KM, and FcγR alleles. Plasma samples from these subjects were also characterized for IgG antibodies to cyclin B1. No significant associations were found between any genetic markers and the level of anticyclin B1 antibodies in CA patients. In AA patients, however, homozygosity for the valine allele at the FcγRIIIa locus was strongly associated with low antibody responsiveness to cyclin B1 (p = 0.0007). Since immunity to cyclin B1 has been shown to play a protective role, these results may, at least in part, explain the disproportionately higher rate of mortality in AA patients with prostate cancer.

Keywords

Cyclin B1 Antibody response FcγR GM KM 

Notes

Acknowledgments

This work was supported in part by a grant from the US Department of Defense (W81XWH-10-1-0479) and by the Biorepository & Research Pathology Services Shared Resource, Hollings Cancer Center, Medical University of South Carolina. We are grateful to the patients and their physicians for their participation and blood donation. We thank Shizhong Bu and Laurel Black for assistance in genotyping and ELISA assays.

References

  1. Balbín M, Grubb A, Abrahamson M, Grubb R (1991) Determination of allotypes G1m(f) and G1m(z) at the genomic level by subclass-specific amplification of DNA and use of allele-specific probes. Exp Clin Immunogenet 8:88–95PubMedGoogle Scholar
  2. Balbín M, Grubb A, de Lange GG, Grubb R (1994) DNA sequences specific for Caucasian G3m(b) and (g) allotypes: allotyping at the genomic level. Immunogenetics 39:187–193PubMedCrossRefGoogle Scholar
  3. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F (2009) Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27:1122–1129PubMedCrossRefGoogle Scholar
  4. Brusco A, de Lange GG, Boccazzi C, Carbonara AO (1995) Molecular characterization of G2m(n+) and G2m(n-) allotypes. Immunogenetics 42:414–417PubMedCrossRefGoogle Scholar
  5. Egloff AM, Weissfeld J, Land SR, Finn OJ (2005) Evaluation of anti-cyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci 1062:29–40PubMedCrossRefGoogle Scholar
  6. Jiang XM, Arepally G, Poncz M, McKenzie SE (1996) Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods 199:55–59PubMedCrossRefGoogle Scholar
  7. Kallakury BV, Sheehan CE, Rhee SJ, Fisher HA, Kaufman RP Jr, Rifkin MD, Ross JS (1999) The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2. Cancer 85:1569–1576Google Scholar
  8. Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, Chan EK, Tan EM (2003) Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9:5120–5126PubMedGoogle Scholar
  9. Lefranc MP, Lefranc G (2012) Human Gm, Km, and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism. Meth Mol Biol 882:635–680CrossRefGoogle Scholar
  10. Lehrnbecher T, Foster CB, Zhu S, Leitman SF, Goldin LR, Huppi K, Chanock SJ (1999) Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 94:4220–4232PubMedGoogle Scholar
  11. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A (1996) Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 56:4159–4163PubMedGoogle Scholar
  12. Moxley G, Gibbs RS (1992) Polymerase chain reaction-based genotyping for allotypic markers of immunoglobulin kappa shows allelic association of Km with kappa variable segment. Genomics 13:104–108PubMedCrossRefGoogle Scholar
  13. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789–1796PubMedCrossRefGoogle Scholar
  14. Namboodiri AM, Pandey JP (2011) Differential inhibition of trastuzumab and cetuximab induced cytotoxicity of cancer cells by IgG1 expressing different GM allotypes. Clin Exp Immunol 166:361–365PubMedCrossRefGoogle Scholar
  15. Pandey JP, Shannon BT, Tsang KY, Fudenberg HH, Camblin JG (1982) Heterozygosity at Gm loci associated with humoral immunity to osteosarcoma. J Exp Med 155:1228–1232PubMedCrossRefGoogle Scholar
  16. Pandey JP, Nietert PJ, Mensdorff-Pouilly S, Klaamas K, Kurtenkov O (2008) Immunoglobulin allotypes influence antibody responses to mucin 1 in patients with gastric cancer. Cancer Res 68:4442–4446PubMedCrossRefGoogle Scholar
  17. Pandey JP, Nietert PJ, Klaamas K, Kurtenkov O (2009) A genetic variant of immunoglobulin γ2 is strongly associated with natural immunity to mucin 1 in patients with breast cancer. Canc Immunol Immunother 58:2025–2029CrossRefGoogle Scholar
  18. Pandey JP, Namboodiri AM, Kurtenkov O, Nietert PJ (2010) Genetic regulation of antibody responses to human epidermal growth factor receptor 2 (HER-2) in breast cancer. Hum Immunol 71:1124–1127PubMedCrossRefGoogle Scholar
  19. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18:2695–2703PubMedCrossRefGoogle Scholar
  20. Stockmeyer B, Valerius T, Repp IR, Heijnen IA, Bühring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JG (1997) Preclinical studies with FcγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu over expressing breast cancer. Cancer Res 57:696–670PubMedGoogle Scholar
  21. Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, Lin W, Chapoval A, Schulze DH, Tian G, Strome SE (2009) FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Canc Immunol Immunother 58:997–1006CrossRefGoogle Scholar
  22. Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ (2009a) Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci U S A 106:14010–14015PubMedCrossRefGoogle Scholar
  23. Vella LA, Yu M, Phillips AB, Finn OJ (2009b) Immunity against cyclin B1 tumor antigen delays development of spontaneous cyclin B1-positive tumors in p53 (−/−) mice. Ann N Y Acad Sci 1174:68–73PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Janardan P. Pandey
    • 1
  • Aryan M. Namboodiri
    • 1
  • Emily Kistner-Griffin
    • 2
  1. 1.Department of Microbiology and ImmunologyMedical University of South CarolinaCharlestonUSA
  2. 2.Department of MedicineMedical University of South CarolinaCharlestonUSA

Personalised recommendations